Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of incretin-based obesity medication on fat-free mass and physical function
NL-OMON58608Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label trial of tirzepatide in obesity and Overweight (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Composition of weight loss after 12 months of therapy and Composition of recurrent weight gain after discontinuation. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NL-OMON58608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58608.